FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976109743> ?p ?o ?g. }

• W1976109743 endingPage "170" @default.
• W1976109743 startingPage "170" @default.
• W1976109743 abstract "Immune globulin is frequently given in the post-transplant phase of allogeneic HSCT as part of pre-emptive anti-CMV therapy. The goal of therapy is to reduce the incidence of CMV reactivation and the subsequent sequelae of CMV disease, to minimize GVHD, and to limit bacterial infections. Previous IGG replacement strategies provided scheduled IGIV replacement empirically, without regard for physiologic hypogammaglobulinemia. The primary aim of this study was to examine whether anti-CMV hyperimmune globulin (Cytogam®) versus standard IGIV reduced the incidence of CMV activation in hypogammaglobulinemic patients. Ablative or nonmyeloablative, CMV+, AHSCT patients were monitored biweekly for IGG levels and received 200 mg/kg QOW of their designated agent if their IGG was < 400 mg/dl during the first 120 days after HSCT. Weekly CMV screening was performed. Antiviral therapy was begun for evidence of molecular reactivation. A quantitative PCR based assay was used in the majority of patients and 2 consecutive values <400 copies or 1 value >400 copies resulted in initiation of antiviral therapy. Ninety patients were enrolled at OHSU between 09/00 and 07/04. Forty-six were randomized to IGIV and 44 to Cytogam®. Three patients randomized to Cytogam® received 1 dose of IGIV and 4 patients received additional IGIV for therapeutic reasons: ITP(1), CMV infection (2), parvovirus (1). Groups were demographically similar for age, gender, and transplant type (URD vs sib). Sixty-two of 90 (69%) patients completed 120 days, 29 (32%) have completed 2 years of follow-up, and 8 are still being actively followed. Forty-two of 90 patients never had an IGG < 400 and received no study drug. Twenty Cytogam® and 28 IVIG patients received study drug by 2 years. Eighteen of 21 patients receiving IVIG and 9/16 patients receiving Cytogam® had CMV activation in the first 120 days (P < .05) (Table1). There were 2 cases of CMV disease: IGIV-colitis [survived], Cytogam®-pneumonia [perished]). There were no deaths attributed to either drug and a single related adverse event was recorded, rigors related to the too rapid infusion of Cytogam®. Of the 28 early deaths on this study, 10 were from infections, 3 graft failure, 5 pulmonary, 4 recurrence, 3 GVHD, 1 MOF, and 1 other. In this small study of hypogammaglobulinemic AHSCT patients, IGG replacement with Cytogam® was associated with decreased rates of CMV activation in the first 120 days.Table 1Overall ResultsDrug/CMV Status (all patients)Cytogam R N = 41IGIV N = 49No drug/no CMV1010No drug/CMV Activation1111Drug/no CMV118Drug/CMV activation920 Open table in a new tab" @default.
• W1976109743 created "2016-06-24" @default.
• W1976109743 creator A5012691456 @default.
• W1976109743 creator A5039745586 @default.
• W1976109743 creator A5040902592 @default.
• W1976109743 creator A5041785705 @default.
• W1976109743 creator A5049897626 @default.
• W1976109743 creator A5051210012 @default.
• W1976109743 creator A5061899912 @default.
• W1976109743 creator A5082092102 @default.
• W1976109743 creator A5087950597 @default.
• W1976109743 date "2006-02-01" @default.
• W1976109743 modified "2023-09-26" @default.
• W1976109743 title "A phase II randomized open-label study anti-CMV hyperimmune globulin vs standard IGIV for prevention of cytomegalovirus (CMV) reactivation in hypogammaglobulinemic adult allogeneic hematopoietic stem cell transplants (AHSCT)" @default.
• W1976109743 doi "https://doi.org/10.1016/j.bbmt.2005.12.015" @default.
• W1976109743 hasPublicationYear "2006" @default.
• W1976109743 type Work @default.
• W1976109743 sameAs 1976109743 @default.
• W1976109743 citedByCount "0" @default.
• W1976109743 crossrefType "journal-article" @default.
• W1976109743 hasAuthorship W1976109743A5012691456 @default.
• W1976109743 hasAuthorship W1976109743A5039745586 @default.
• W1976109743 hasAuthorship W1976109743A5040902592 @default.
• W1976109743 hasAuthorship W1976109743A5041785705 @default.
• W1976109743 hasAuthorship W1976109743A5049897626 @default.
• W1976109743 hasAuthorship W1976109743A5051210012 @default.
• W1976109743 hasAuthorship W1976109743A5061899912 @default.
• W1976109743 hasAuthorship W1976109743A5082092102 @default.
• W1976109743 hasAuthorship W1976109743A5087950597 @default.
• W1976109743 hasBestOaLocation W19761097431 @default.
• W1976109743 hasConcept C120665830 @default.
• W1976109743 hasConcept C121332964 @default.
• W1976109743 hasConcept C126322002 @default.
• W1976109743 hasConcept C159654299 @default.
• W1976109743 hasConcept C203014093 @default.
• W1976109743 hasConcept C2522874641 @default.
• W1976109743 hasConcept C2776409557 @default.
• W1976109743 hasConcept C2777408962 @default.
• W1976109743 hasConcept C2777732132 @default.
• W1976109743 hasConcept C2777805810 @default.
• W1976109743 hasConcept C2780727368 @default.
• W1976109743 hasConcept C2780882860 @default.
• W1976109743 hasConcept C2911091166 @default.
• W1976109743 hasConcept C61511704 @default.
• W1976109743 hasConcept C71924100 @default.
• W1976109743 hasConcept C90924648 @default.
• W1976109743 hasConceptScore W1976109743C120665830 @default.
• W1976109743 hasConceptScore W1976109743C121332964 @default.
• W1976109743 hasConceptScore W1976109743C126322002 @default.
• W1976109743 hasConceptScore W1976109743C159654299 @default.
• W1976109743 hasConceptScore W1976109743C203014093 @default.
• W1976109743 hasConceptScore W1976109743C2522874641 @default.
• W1976109743 hasConceptScore W1976109743C2776409557 @default.
• W1976109743 hasConceptScore W1976109743C2777408962 @default.
• W1976109743 hasConceptScore W1976109743C2777732132 @default.
• W1976109743 hasConceptScore W1976109743C2777805810 @default.
• W1976109743 hasConceptScore W1976109743C2780727368 @default.
• W1976109743 hasConceptScore W1976109743C2780882860 @default.
• W1976109743 hasConceptScore W1976109743C2911091166 @default.
• W1976109743 hasConceptScore W1976109743C61511704 @default.
• W1976109743 hasConceptScore W1976109743C71924100 @default.
• W1976109743 hasConceptScore W1976109743C90924648 @default.
• W1976109743 hasIssue "2" @default.
• W1976109743 hasLocation W19761097431 @default.
• W1976109743 hasOpenAccess W1976109743 @default.
• W1976109743 hasPrimaryLocation W19761097431 @default.
• W1976109743 hasRelatedWork W1939317775 @default.
• W1976109743 hasRelatedWork W1996182916 @default.
• W1976109743 hasRelatedWork W203126751 @default.
• W1976109743 hasRelatedWork W2034250228 @default.
• W1976109743 hasRelatedWork W2107517536 @default.
• W1976109743 hasRelatedWork W271486173 @default.
• W1976109743 hasRelatedWork W2803613523 @default.
• W1976109743 hasRelatedWork W3015454806 @default.
• W1976109743 hasRelatedWork W3029049270 @default.
• W1976109743 hasRelatedWork W4248798618 @default.
• W1976109743 hasVolume "12" @default.
• W1976109743 isParatext "false" @default.
• W1976109743 isRetracted "false" @default.
• W1976109743 magId "1976109743" @default.
• W1976109743 workType "article" @default.